Understanding the Term 'Hypersecretion Glaucoma'
At a Glance
Hypersecretion glaucoma is an older term for high eye pressure thought to result from excess fluid production. Modern care looks for the actual cause—such as impaired drainage, steroid use, or eye inflammation—and lowers pressure to protect the optic nerve.
If you have heard the term hypersecretion glaucoma, you may find that it does not appear in modern brochures or current clinical guidelines. It is important to know that while the name itself has largely fallen out of favor in modern ophthalmology, the high eye pressure it describes is a very real clinical finding that doctors manage every day.
First, it is helpful to distinguish between two related concepts: ocular hypertension means your eye pressure is high but there is no detectable damage to your optic nerve yet. Glaucoma means that the pressure has caused characteristic damage to the optic nerve or your visual field. Not everyone with high pressure has glaucoma, but high pressure is the primary risk factor.
Historically, the “hypersecretion” label was used to describe a specific theory: that the eye’s pressure was rising because it was producing too much fluid, rather than the more common problem where the fluid cannot drain out [1][2]. Today, most specialists view this term as a historical way of thinking about the eye’s fluid balance rather than a distinct, standalone disease.
The ‘Faucet and Drain’ Concept
To understand why your doctor might have used this term, it helps to look at how the eye maintains its shape and health through aqueous humor dynamics (the way fluid moves in and out of the eye). You can think of your eye like a sink with a faucet that is always running and a drain that is always open [2][3].
- The Faucet (The Ciliary Body): This structure behind the iris constantly produces a clear fluid called aqueous humor. This fluid carries nutrients to parts of the eye that don’t have blood vessels [2].
- The Drain (The Trabecular Meshwork): This is the eye’s primary drainage system. In most types of glaucoma, this “drain” becomes clogged or resistant, causing fluid to back up and pressure to rise [4][1].
The theory of hypersecretion suggested that the “faucet” was turned up too high [1]. If the faucet produces fluid faster than even a healthy drain can clear it, the intraocular pressure (IOP) increases [2][3].
Why the Term Is Controversial
In the past, doctors used a test called tonography to try and estimate how well the eye’s drain was working [5]. If the drain seemed mechanically open but the pressure was still high, they often concluded the eye must be “hypersecreting” fluid.
However, modern research has challenged this idea for several reasons:
- Measurement Difficulty: Accurately measuring exactly how much fluid the eye produces is extremely difficult in a clinical setting [6][7].
- Hidden Drain Issues: Many cases once thought to be “overproduction” were later found to have subtle drainage problems that older tests simply couldn’t detect. Even if the drain is anatomically “open,” it may still have microscopic resistance [8][9].
- Secondary Causes: High pressure is often found to be a “secondary” effect of something else—such as a reaction to steroid medications, underlying inflammation (uveitis), or rare vascular issues—rather than a primary overproduction of fluid [10][11].
Because of these findings, modern guidelines categorize these patients based on the true underlying mechanism—whether that is primary open-angle glaucoma, a specific secondary glaucoma, or simply ocular hypertension [10][12].
Focus on Treatment, Not the Label
The most important takeaway for you is that the result (elevated pressure) is what matters for your vision. The goal of treatment is always the same: to lower the pressure to a safe level to protect the optic nerve [13][12].
Standard treatments are highly effective at managing the pressure, even if the label used to describe it is outdated:
- “Inflow” Medications: Some eye drops, such as beta-blockers or carbonic anhydrase inhibitors, specifically work by “turning down the faucet” (reducing fluid production) [2][14].
- “Outflow” Medications: Other drops, such as prostaglandin analogs, help the eye’s drainage pathways clear fluid more efficiently [14][15].
- Laser and Surgical Options: Procedures like Selective Laser Trabeculoplasty (SLT) or MIGS focus on improving the drain’s function to lower pressure [9][16].
While the term “hypersecretion glaucoma” might feel confusing, your care team is focusing on the same evidence-based goals used for all glaucoma patients: finding your target IOP (the pressure range where your eye is safe) and monitoring your vision closely through imaging and field tests [13][17].
Common questions in this guide
What does hypersecretion glaucoma mean?
Is hypersecretion glaucoma still used as a current diagnosis?
Does high eye pressure mean that I have glaucoma?
Can steroid medicines or eye inflammation cause high eye pressure?
How is high eye pressure treated if hypersecretion is suspected?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What findings in my exam led to the mention of 'hypersecretion' as a possible cause?
- 2.Since hypersecretion is a rare or historical label, do my tests show that my eye's 'drain' (outflow facility) is working normally?
- 3.Are there specific secondary causes, like steroid use or inflammation, that could be mimicking a high-fluid-production state?
- 4.Do I currently have 'ocular hypertension' (high pressure without damage) or established glaucoma?
- 5.Is there a specific reason we are choosing 'inflow' medications (like beta-blockers) over 'outflow' medications for my case?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (17)
- 1
The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment.
Braunger BM, Fuchshofer R, Tamm ER
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2015; (95(Pt B)):173-81.
PMID: 25957840 - 2
Controversies in Glaucoma: Current Medical Treatment and Drug Development.
Bucolo C, Platania CB, Reibaldi M, et al.
Current pharmaceutical design 2015; (21(32)):4673-81 doi:10.2174/1381612821666150909095553.
PMID: 26350532 - 3
Regulation of intraocular pressure by microRNA cluster miR-143/145.
Li X, Zhao F, Xin M, et al.
Scientific reports 2017; (7(1)):915 doi:10.1038/s41598-017-01003-z.
PMID: 28424493 - 4
Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Sit AJ, Gupta D, Kazemi A, et al.
American journal of ophthalmology 2021; (226()):262-269 doi:10.1016/j.ajo.2021.01.019.
PMID: 33524367 - 5
Objective Grading of Tonography Tracings for the Measurement of Outflow Facility.
Sit AJ, Toris CB, Gulati V, et al.
Translational vision science & technology 2025; (14(2)):10 doi:10.1167/tvst.14.2.10.
PMID: 39913125 - 6
Why Low Outflow Facility and Low Aqueous Production May Be Risk Factors in Endoscopic Cyclophotocoagulation: A Goldmann-Based Perspective.
Tanito M
Cureus 2026; (18(4)):e107217 doi:10.7759/cureus.107217.
PMID: 42006522 - 7
Aqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects.
Kazemi A, Reitinger JC, Toris CB, et al.
Journal of glaucoma 2025; (34(12)):1056-1064 doi:10.1097/IJG.0000000000002585.
PMID: 40341017 - 8
Aqueous Humor Dynamics in Uveitic Eyes.
Alaghband P, Baneke AJ, Galvis E, et al.
American journal of ophthalmology 2019; (208()):347-355 doi:10.1016/j.ajo.2019.08.018.
PMID: 31473215 - 9
Mechanism of Action of Selective Laser Trabeculoplasty and Predictors of Response.
Gulati V, Fan S, Gardner BJ, et al.
Investigative ophthalmology & visual science 2017; (58(3)):1462-1468 doi:10.1167/iovs.16-20710.
PMID: 28264102 - 10
[Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].
Greslechner R, Helbig H, Spiegel D
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2022; (119(5)):533-546 doi:10.1007/s00347-022-01630-6.
PMID: 35471612 - 11
[Glaucoma due to elevated episcleral venous pressure].
Greslechner R, Oberacher-Velten I
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2019; (116(5)):423-429 doi:10.1007/s00347-018-0828-4.
PMID: 30506098 - 12
Primary open-angle glaucoma.
Weinreb RN, Leung CK, Crowston JG, et al.
Nature reviews. Disease primers 2016; (2()):16067 doi:10.1038/nrdp.2016.67.
PMID: 27654570 - 13
Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma.
Sihota R, Angmo D, Ramaswamy D, Dada T
Indian journal of ophthalmology 2018; (66(4)):495-505 doi:10.4103/ijo.IJO_1130_17.
PMID: 29582808 - 14
Current management of glaucoma.
Lusthaus J, Goldberg I
The Medical journal of Australia 2019; (210(4)):180-187 doi:10.5694/mja2.50020.
PMID: 30767238 - 15
FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Sharif NA, Odani-Kawabata N, Lu F, Pinchuk L
Experimental eye research 2023; (229()):109415 doi:10.1016/j.exer.2023.109415.
PMID: 36803996 - 16
Trabecular Meshwork-Based MIGS: Efficacy, Technique Variability, and Wound Healing-A Comprehensive Review.
Butt FR, Dhivagaran T, Stasso J, et al.
Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041490.
PMID: 41753178 - 17
Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment.
Konstas AG, Kahook MY, Araie M, et al.
Advances in therapy 2018; (35(11)):1775-1804 doi:10.1007/s12325-018-0812-z.
PMID: 30341506
This page explains the historical term hypersecretion glaucoma for informational purposes only and does not constitute medical advice. Your ophthalmologist should interpret your eye-pressure measurements and choose care for your specific situation.
Get notified when new evidence is published on hypersecretion glaucoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.